What is Leerink Partnrs’ Estimate for MRSN Q1 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a note issued to investors on Monday, March 3rd. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.14) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million during the quarter, compared to analyst estimates of $7.71 million.

Several other analysts also recently weighed in on the company. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating on the stock. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a research note on Monday. Finally, Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.25.

Mersana Therapeutics Stock Up 5.9 %

Shares of MRSN stock opened at $0.51 on Tuesday. Mersana Therapeutics has a 1-year low of $0.46 and a 1-year high of $6.28. The stock’s fifty day moving average price is $0.82 and its 200 day moving average price is $1.56. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The company has a market cap of $62.79 million, a price-to-earnings ratio of -0.83 and a beta of 1.39.

Institutional Trading of Mersana Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Novo Holdings A S purchased a new stake in shares of Mersana Therapeutics in the fourth quarter worth about $6,078,000. Rock Springs Capital Management LP boosted its stake in shares of Mersana Therapeutics by 12.6% in the fourth quarter. Rock Springs Capital Management LP now owns 3,431,684 shares of the company’s stock worth $4,907,000 after buying an additional 384,902 shares during the last quarter. State Street Corp boosted its stake in shares of Mersana Therapeutics by 1.6% in the third quarter. State Street Corp now owns 2,725,394 shares of the company’s stock worth $5,151,000 after buying an additional 43,339 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Mersana Therapeutics in the fourth quarter worth about $3,768,000. Finally, Geode Capital Management LLC boosted its stake in shares of Mersana Therapeutics by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,442,250 shares of the company’s stock worth $3,493,000 after buying an additional 29,035 shares during the last quarter. Hedge funds and other institutional investors own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.